Biocon explores $4.5 billion merger with Biocon Biologics
pre-market1 source ↓written by the desknot a recommendation
- with its biosimilars
- $4.5 billion merger
- in Biocon Biologics
- 90.20% stake
- from previous acquisitions
- $1.2 billion debt
Biocon Ltd is considering a $4.5 billion merger with its biosimilars arm, Biocon Biologics. The company is evaluating options including a share swap and an IPO, as it seeks to optimize value. Biocon currently holds a 90.20% stake in Biocon Biologics, which aims to reduce its $1.2 billion debt from previous acquisitions.
Not investment advice. For informational purposes only.